Skip to main
PFE
PFE logo

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 31 analyst ratings
Hold
Strong Buy 23%
Buy 13%
Hold 61%
Sell 3%
Strong Sell 0%

Bulls say

Pfizer has demonstrated a strong financial performance in the fourth quarter of 2024, surpassing both internal and consensus estimates with higher-than-expected sales from key products, including Comirnaty, Paxlovid, Eliquis, and Ibrance. The company's continued focus on managing its cost base and pursuing business development opportunities, alongside an expected stabilization of COVID-19 revenues, reinforces a positive outlook for 2025. Additionally, with nearly 50% of sales coming from international markets, particularly strong contributions from emerging economies, Pfizer is well-positioned for future growth despite potential fluctuations in COVID-related product demand.

Bears say

Pfizer's stock faces a negative outlook primarily due to disappointing commercial execution on key marketed products such as Padcev, Abrysvo, and Paxlovid, which could dampen investor confidence. Additionally, potential regulatory setbacks and clinical data disappointments concerning line extensions and pipeline assets may hinder future growth prospects. Concerns surrounding U.S. drug pricing reform further contribute to the negative sentiment towards Pfizer, raising skepticism about the company's ability to navigate the evolving pharmaceutical landscape effectively.

Pfizer (PFE) has been analyzed by 31 analysts, with a consensus rating of Hold. 23% of analysts recommend a Strong Buy, 13% recommend Buy, 61% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Hold based on their latest research and market trends.

According to 31 analysts, Pfizer (PFE) has a Hold consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.